Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 26 of the 48 sources its claims cite were checked for support.
Abstract
BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease. METHODS: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of treatment. The primary outcome was progression-free survival. RESULTS: A total of 419 patients underwent randomization (208 to receive cilta-cel and 211 to receive standard care). At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group. More patients in the cilta-cel group than in the standard-care group had an overall response (84.6% vs. 67.3%), a complete response or better (73.1% vs. 21.8%), and an absence of minimal residual disease (60.6% vs. 15.6%). Death from any cause was reported in 39 patients and 46 patients, respectively (hazard ratio, 0.78; 95% CI, 0.5 to 1.2). Most patients reported grade 3 or 4 adverse events during treatment. Among the 176 patients who received cilta-cel in the as-treated population, 134 (76.1%) had cytokine release syndrome (grade 3 or 4, 1.1%; no grade 5), 8 (4.5%) had immune effector cell-associated neurotoxicity syndrome (all grade 1 or 2), 1 had movement and neurocognitive symptoms (grade 1), 16 (9.1%) had cranial nerve palsy (grade 2, 8.0%; grade 3, 1.1%), and 5 (2.8%) had CAR-T-related peripheral neuropathy (grade 1 or 2, 2.3%; grade 3, 0.6%). CONCLUSIONS: A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).
Overview
CoChat Summary
TL;DR
In CARTITUDE-4, a single cilta-cel infusion significantly improved progression-free survival versus physician’s choice standard care in lenalidomide-refractory multiple myeloma after one to three prior lines. Cilta-cel also produced higher response and MRD-negativity rates, with mostly manageable CAR-T-specific adverse events.
Key findings
- At a median follow-up of 15.9 months, median progression-free survival was not reached with cilta-cel versus 11.8 months with standard care (HR, 0.26; 95% CI, 0.18 to 0.38; P<0.001); 12-month progression-free survival was 75.9% vs. 48.6%.
- Cilta-cel produced higher overall response (84.6% vs. 67.3%), complete response or better (73.1% vs. 21.8%), and MRD negativity (60.6% vs. 15.6%).
- Overall survival was immature: death from any cause occurred in 39 cilta-cel patients and 46 standard-care patients (HR, 0.78; 95% CI, 0.5 to 1.2; P=0.26); 12-month survival was 84.1% vs. 83.6%.
- Grade 3 or 4 adverse events occurred in 96.6% vs. 94.2%; among 176 as-treated cilta-cel patients, cytokine release syndrome occurred in 76.1% (grade 3 or 4, 1.1%; no grade 5), ICANS in 4.5% (all grade 1 or 2), cranial nerve palsy in 9.1%, and CAR-T-related peripheral neuropathy in 2.8%.
Methods
- Phase 3, randomized, open-label trial at 81 sites in the United States, Europe, Asia, and Australia; 419 patients with lenalidomide-refractory multiple myeloma after one to three prior lines, ECOG performance-status score ≤1, and no prior CAR-T or BCMA-targeted therapy were assigned 1:1 to cilta-cel (208) or standard care (211; PVd or DPd).
- Cilta-cel patients received apheresis, bridging therapy, lymphodepletion, and a single cilta-cel infusion (target dose, 0.75×10^6 CAR+ viable T cells/kg); standard-care patients received DPd or PVd until progression, with no protocol-permitted crossover.
- Primary outcome was progression-free survival; efficacy was analyzed in the intention-to-treat population with Kaplan-Meier estimates, a stratified weighted log-rank test, and stratified Cox regression; adverse events were evaluated in the safety population and CAR-T-specific events in the as-treated population.
Limitations
- Stated: two highly efficacious triplet regimens—daratumumab, carfilzomib, and dexamethasone and isatuximab, carfilzomib, and dexamethasone—were not approved at trial initiation and could not be included as standard-care options.
- Stated: early progression or death during weeks 0 to 8 was higher in the cilta-cel group and all occurred before cilta-cel infusion; this may have been due to lower bridging doses of DPd/PVd, and the benefit did not become apparent until 3 months. Overall survival data were immature.
- Evident: the trial was open-label, the sponsor was involved in data collection, analysis, and interpretation, and median follow-up was 15.9 months, limiting assessment of overall survival; crossover from standard care to cilta-cel was not permitted.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 86 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In the phase 1b-2 CARTITUDE-1 trial involving patients who had received at least three lines of therapy, the median progressionfree survival was 34.9 months. 10-12”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Disputedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results > Efficacy section states that median progression-free survival was not reached at a median follow-up of 27.7 months, contrary to the claimed 34.9 months. The Methods > Study Design and Treatment section confirms that CARTITUDE-1 was a phase Ib/II trial, but its eligibility criteria also allowed some patients with fewer than three prior lines of therapy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [12] 12. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/ refractory multiple myeloma. J Clin Oncol 2023; 41: Suppl: 8009. abstract. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“High treatment attrition - only 13 to 35% of patients receive four or more lines of therapy - also highlights the need to use effective therapies early. 9”
What the sources say
- Supportedcites [9] 9. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 2020; 20: 1087. source
Table 4 (Results, Attrition by LOT) shows that 2,971 of 22,062 non-transplant patients (13.5%) and 954 of 2,763 transplant patients (34.5%) received a fourth line of therapy. The Conclusion links high attrition to the need for effective treatment early. These percentages concern patients in the study who received at least one line of therapy, not all patients diagnosed with multiple myeloma. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The frequency of lenalidomide resistance early in the treatment journey is increasing, 1,8”
What the sources say
- Supportedcites [1] 1. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program 2020; 2020: 248-58. source
In the Introduction sections “Changes in frontline treatment” and “Refractory to lenalidomide,” the paper says that increasing frontline use of lenalidomide is leading to an increasing fraction of patients with lenalidomide-refractory disease at first relapse. This supports the claim about resistance occurring more frequently early in the treatment journey. (LLM, conf=0.94)
- Supportedcites [8] 8. de Arriba de la Fuente F, Montes Gaisán C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. Cancers (Basel) 2022; 15: 155. source
The Introduction states that, with extensive use of frontline lenalidomide-based therapies, lenalidomide refractoriness early in the disease course is increasingly common. This directly supports the citing sentence’s paraphrase. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The incidence of movement and neurocognitive adverse events was also lower in CARTITUDE-4 (0.6%) than in CARTITUDE-1 (6.0%)”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results section identifies parkinsonism as previously termed movement and neurocognitive adverse events, and the Discussion reports a 6% incidence in CARTITUDE-1. The paper does not give a CARTITUDE-4 incidence of 0.6%; it instead reports less than 0.5% across other cilta-cel studies without identifying CARTITUDE-4. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“which suggests that cilta-cel may have a better side-effect profile when used earlier in treatment. 10,11”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Discussion (page not available) says earlier use of cilta-cel may improve long-term outcomes and notes that prior treatments in this heavily pretreated group are associated with an increased risk of secondary primary malignancies. It does not say that cilta-cel itself would have fewer side effects if used earlier, so the specific safety comparison remains unsupported. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
43 more claims
Create a free account to see all 109 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients in the cilta-cel arm of CARTITUDE-4 who had increased tumor burden after bridging therapy or lymphodepletion were assessed as having PD and could receive cilta-cel as subsequent therapy at the investigator ' s discretion 14 ; in KarMMa-3, these patients were permitted to remain on study.”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably in KarMMa-3, 54% (207/386) of patients were enrolled in the United States compared with 15% (64/419) in CARTITUDE-4. 14”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Both ide-cel and cilta-cel have subsequently shown superiority over standard relapsed myeloma regimens in randomized trials conducted earlier in the disease course (Table 9).159,160”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [160]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“During treatment, infections occurred in 129 patients (62.0%) in the cilta-cel group and in 148 (71.2%) in the standard-care group; of these infections, 26.9% and 24.5%, respectively, were of grade 3 or 4.”
Reported 26.9 · recomputed 43.410853
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Immune effector cell-associated neuro- toxicity syndrome and associated symptoms | 8/176 (4.5) | 1/176 (0.1)”
Reported 0.1 · recomputed 0.568182
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“MRD negativity at any time during the trial occurred in 60.6% of the patients in the cilta-cel group and in 15.6% of those in the standard-care group, for a risk ratio of 2.2”
Reported 2.2 · recomputed 3.884615
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citationDimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430
Self-citationMoreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392
Self-citationRichardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386
Self-citationDimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., Moreau, P., Baldini, L., Symeonidis, A., Bila, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00128-5 · Cited by 344
Self-citationMultiple myeloma: patient outcomes in real‐world practice
Yong, K., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Raab, M. S., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14213 · Cited by 326
Self-citationCohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N. W. C. J., Arnulf, B., Mateos, M.-V., Lendvai, N., Jackson, C. C., De Braganca, K. C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00629-1 · Cited by 308
Self-citationInterpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Richardson, P. G., San Miguel, J. F., Moreau, P., Hajek, R., Dimopoulos, M. A., Laubach, J. P., Palumbo, A., Luptakova, K., Romanus, D., Skacel, T., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0141-0 · Cited by 228
Self-citationUsmani, S. Z., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Gavriatopoulou, M., Oriol, A., Rabin, N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00579-9 · Cited by 171
Self-citationFonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07503-y · Cited by 127
Lin, Y., Martin, T. G., Usmani, S. Z., Berdeja, J. G., Jakubowiak, A. J., Agha, M. E., Cohen, A. D., Deol, A., Htut, M., Lesokhin, A. M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.8009 · Cited by 120
Self-citationZUCKER, D. M., & LAKATOS, E. (1990) · Biometrika · doi:10.1093/biomet/77.4.853 · Cited by 114
Designing therapeutic cancer vaccine trials with delayed treatment effect: Z. XU ET AL.
Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017) · Statistics in Medicine · doi:10.1002/sim.7157 · Cited by 76
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, F., Montes Gaisán, C., & de la Rubia Comos, J. (2022) · Cancers · doi:10.3390/cancers15010155 · Cited by 28
Sequencing multiple myeloma therapies with and after antibody therapies
van de Donk, N. W. C. J. (2020) · Hematology · doi:10.1182/hematology.2020000109 · Cited by 27
Self-citationVan De Donk, N. W., Agha, M., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W. W. H., Schecter, J. M., De Braganca, K. C., Jackson, C. C., et al. (2022) · Blood · doi:10.1182/blood-2022-159169 · Cited by 25
Self-citationDimopoulos, M. A., Quach, H., Mateos, M., Landgren, O., Leleu, X. P., Siegel, D. S. D., Weisel, K. C., Gavriatopoulou, M., Oriol, A., Rabin, N. K., et al. (2020) · Blood · doi:10.1182/blood-2020-137602 · Cited by 21
Self-citationRodríguez‐Lobato, L. G., Pereira, A., Fernández de Larrea, C., Cibeira, M. T., Tovar, N., Jiménez‐Segura, R., Moreno, D. F., Oliver‐Caldés, A., Rosiñol, L., & Bladé, J. (2022) · British Journal of Haematology · doi:10.1111/bjh.17888 · Cited by 19
Moreau, P., Dimopoulos, M. A. C., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Casca, F., Mace, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.013 · Cited by 18
Self-citationDhakal, B., Einsele, H., Potluri, R., Schecter, J., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., He, J., et al. (2022) · HemaSphere · doi:10.1097/01.hs9.0000846468.64341.f1 · Cited by 9
Self-citationEinsele, H., Cohen, A. D., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., Schecter, J. M., De Braganca, K. C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.8020 · Cited by 7
Self-citationDhakal, B., Einsele, H., Potluri, R., Schecter, J., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., He, J., et al. (2022) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/s2152-2650(22)00570-5 · Cited by 3
Self-citationDhakal, B., Einsele, H., Schecter, J. M., Deraedt, W. M., Lendvai, N. K., Slaughter, A., Lonardi, C., Nair, S. C., He, J., Voelker, J., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(22)00571-7 · Cited by 2
Self-citationRodríguez-Lobato, L. G., Pereira, A., Larrea, C. F. D., et al. (2021) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/s2152-2650(21)02251-5
Zucker, D. M., & Lakatos, E. (1990) · Biometrika · doi:10.2307/2337108
Lin, Y., Martin, T., Usmani, S., et al. (2023) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/s2152-2650(23)00862-5
Cited by
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 359
Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
CAR-T cell manufacturing: Major process parameters and next-generation strategies
Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20230903 · Cited by 303
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
Cordas dos Santos, D. M., Tix, T., Shouval, R., Gafter-Gvili, A., Alberge, J.-B., Cliff, E. R. S., Theurich, S., von Bergwelt-Baildon, M., Ghobrial, I. M., Subklewe, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03084-6 · Cited by 287
Metadata
- Authors
- San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N. W. C. J., Dytfeld, D., Sidana, S., Costa, L. J., Oriol, A., Popat, R., Khan, A. M., Cohen, Y. C., Ho, P. J., Griffin, J., Lendvai, N., Lonardi, C., Slaughter, A., Schecter, J. M., Jackson, C. C., Connors, K., Li, K., Zudaire, E., Chen, D., Gilbert, J., Yeh, T.-M., Nagle, S., Florendo, E., Pacaud, L., Patel, N., Harrison, S. J., & Einsele, H.
- Affiliations
- From the Cancer Center Clínica Universidad de Navarra, Centro Investigación Medica Aplicada, Instituto de Investigación de Navarra, Centro Investigación Biomédica en Red Cáncer (CIBERONC), Pamplona (J.S.-M.), the University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro Investigación del Cáncer, CIBERONC, Salamanca (M.-V.M.), the Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (C.F.L.), the Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid (J.M.-L.), and the Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.) — all in Spain; the Medical College of Wisconsin, Milwaukee (B.D.); the University College London Cancer Institute (K.Y.) and University College London Hospitals, NHS Foundat...
- Medical College of Wisconsin (US)
- Inserm (FR)
- University Medical Center Groningen (NL)
- Poznan University of Medical Sciences (PL)
- University College London Hospitals NHS Foundation Trust (GB)
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- ORCID
- Dhakal, Binod
- Yong, Kwee
- Spencer, Andrew
- Anguille, Sébastien
- Mateos, María-Victoria
- Moreau, Philippe
- Touzeau, Cyrille
- Leleu, Xavier
- Avivi, Irit
- Ishida, Tadao
- Kim, Seok Jin
- Roeloffzen, Wilfried
- Dytfeld, Dominik
- Sidana, Surbhi
- Costa, Luciano J.
- Oriol, Albert
- Popat, Rakesh
- Khan, Abdullah M.
- Ho, P. Joy
- Lendvai, Nikoletta
- Schecter, Jordan M.
- Jackson, Carolyn C.
- Li, Katherine
- Chen, Diana
- Nagle, Sarah
- Pacaud, Lida
- Patel, Nitin
- Harrison, Simon J.
- Einsele, Hermann
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-07-27
- Volume
- 389
- Issue
- 4
- Pages
- 335-347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4379375986
- Semantic Scholar
- e537b398daa738a9f57ecb0da894878f49df8dae
- Cited by
- 827
- References
- 27
- Citations by year
- 2026: 257 · 2025: 279 · 2024: 230 · 2023: 60
- FWCI
- 169.95
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Legend Biotech USA Inc.
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- cilta-cel, ciltacabtagene autoleucel, lenalidomide-refractory multiple myeloma, progression-free survival, standard of care comparison, cytokine release syndrome, neurotoxicity, non-relapse mortality, minimal residual disease, relapsed/refractory multiple myeloma, adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Lenalidomide, Progression-Free Survival, Humans, Multiple Myeloma, Immunotherapy, Adoptive, Drug Resistance, Neoplasm, Neurotoxicity Syndromes, B-Cell Maturation Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.